Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03071224 · ClinicalTrials.gov registry record · Early Phase 1
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
A Early Phase 1 study of Alzheimer Disease and Healthy Volunteers, sponsored by Invicro.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03071224: Completed Early Phase 1 study of Alzheimer Disease and Healthy Volunteers, sponsored by Invicro.
NCT03071224 is a Early Phase 1 study of Alzheimer Disease and Healthy Volunteers that has completed, run by Invicro. The registered enrollment target is 10 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03071224, a Early Phase 1 study of Alzheimer Disease and Healthy Volunteers, has completed, sponsored by Invicro.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this protocol is to evaluate \[18F\]MK-6240 (also known as \[18F\]MNI-946) a tau targeted radiopharmaceutical.
Primary Outcome
Tracer uptake will be evaluated in regions of interest for analysis of regional \[18F\]MK-6240 binding/uptake and expressed in SUV by using established methods for normalization for 12 AD and 3 HV subjects in Cohort 1, 8 AD and 2 HV subjects in Cohort 2, and 3 AD and 3 HV subjects in Cohort 3. Target regions of interest in the standard volume of interest (VOI) template, will be used for tracer uptake quantitation of potentially increased binding to tau pathology will correspond in particular to
Conditions Studied
Interventions
- DRUG [18F] MNI-946
- DRUG [18F]Florbetapir
Study Locations (1)
Connecticut
- Invicro - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-06 |
| Est. Completion | 2021-06-09 |
| Phase | Early Phase 1 |
What the finished NCT03071224 record still lists
NCT03071224 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which [18F] MNI-946 is the first listed.
NCT03071224 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03071224 about?
NCT03071224 is a clinical study titled "Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein". The overall goal of this protocol is to evaluate \[18F\]MK-6240 (also known as \[18F\]MNI-946) a tau targeted radiopharmaceutical.
What is the current status of trial NCT03071224?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2016-06. Estimated completion is 2021-06-09.
What conditions does trial NCT03071224 study?
This clinical trial studies the following conditions: Alzheimer Disease, Healthy Volunteers.
What interventions are being tested in trial NCT03071224?
The interventions under investigation include: [18F] MNI-946 (DRUG), [18F]Florbetapir (DRUG).
Who is sponsoring clinical trial NCT03071224?
This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03071224 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03071224's enrollment target sits among peer trials
10 291st of 306 higher than 13 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
Neuroinflammation Imaging in AD
RECRUITING · Early Phase 1
-
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
RECRUITING · Early Phase 1
-
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
RECRUITING · Early Phase 1
-
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
RECRUITING · Early Phase 1
-
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia